C12-200|Ionizable Lipid for LNP

Cas No.:	1220890-25-4
Chemical Name:	C12-200
Synonyms:	Tech G 1
SMILES:	C(O)(CCCCCCCCCC)CN(CC(O)CCCCCCCCCC)CCN1CCN(CCN(CCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC)CC(CCCCCCCCCC)O)CC1
Formula:	C₇₀N₅O₅H₁₄₅
M.Wt:	1136.931
Purity:	>95%
Sotrage:	pure form: -20°C/3 years,4°C/2 years; In solvent: -20°C/1 month
Publication:	1. Kevin T. Love, Kerry P. Mahon, Christopher G. Levins, Kathryn A. Whitehead, William Querbes, J. Robert Dorkin, June Qin, William Cantley, Liu Liang Qin, Timothy Racie, Maria Frank-Kamenetsky, Ka Ning Yip, Rene Alvarez, Dinah W. Y. Sah, Antonin de Fougerolles, Kevin Fitzgerald, Victor Koteliansky, Akin Akinc, Robert Langer, Daniel G. Anderson, Proceedings of the National Academy of Sciences, Feb 2010, 107 (5) 1864-1869; DOI: 10.1073/pnas.0910603106 2. Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, Novobrantseva T, Borodovsky A, Fitzgerald K, Koteliansky V, Iwamoto Y, Bohlender M, Meyer S, Lasitschka F, Meder B, Katus HA, Lin C, Libby P, Swirski FK, Anderson DG, Weissleder R, Nahrendorf M. Eur Heart J. 2015 Jun 14;36(23):1478-88. doi: 10.1093/eurheartj/ehu225. Epub 2014 Jun 20. 3. Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW1, DeRosa F1, Mir FF, Fenton OS, Anderson DG. Nano Lett. 2015 Nov 11;15(11):7300-6. doi: 10.1021/acs.nanolett.5b02497. Epub 2015 Oct 20.

Description:

C12-200 is a cationic lipid for Lipid NanoParticles as delivery systems for enabling the therapeutic potential of siRNA, mRNA or CRISPR as they exhibit remarkable in vivo potencies at low doses.C12-200 is a common positive control ionizable lipid for exploring new ionizable lipids. C12-200 is an ionizable lipid with five tails. The tri-palmitoyl-Sglyceryl cysteine linked to the pentapeptide (Pam3)-modified C12-200 iLNPs was developed to deliver tumor antigen mRNA for enhancing the mRNA-mediated cancer immunotherapy. The results of the therapeutic evaluation showed that Pam3- modified C12-200 iLNPs could almost inhibit tumor growth in tumor-bearing mice. To improve delivery efficiency, the formulation was optimized to replace the phospholipids from DSPC to DOPE, and the result showed that optimized formulation induced EPO protein expression was seven times that of the initial formulation,[35] and the formulation has been used in the study for mRNA-mediated human α-galactosidase protein replacement therapy in mice and nonhuman primates.

References:

1. Kevin T. Love, Kerry P. Mahon, Christopher G. Levins, Kathryn A. Whitehead, William Querbes, J. Robert Dorkin, June Qin, William Cantley, Liu Liang Qin, Timothy Racie, Maria Frank-Kamenetsky, Ka Ning Yip, Rene Alvarez, Dinah W. Y. Sah, Antonin de Fougerolles, Kevin Fitzgerald, Victor Koteliansky, Akin Akinc, Robert Langer, Daniel G. Anderson, Proceedings of the National Academy of Sciences, Feb 2010, 107 (5) 1864-1869; DOI: 10.1073/pnas.0910603106 2. Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, Novobrantseva T, Borodovsky A, Fitzgerald K, Koteliansky V, Iwamoto Y, Bohlender M, Meyer S, Lasitschka F, Meder B, Katus HA, Lin C, Libby P, Swirski FK, Anderson DG, Weissleder R, Nahrendorf M. Eur Heart J. 2015 Jun 14;36(23):1478-88. doi: 10.1093/eurheartj/ehu225. Epub 2014 Jun 20. 3. Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW1, DeRosa F1, Mir FF, Fenton OS, Anderson DG. Nano Lett. 2015 Nov 11;15(11):7300-6. doi: 10.1021/acs.nanolett.5b02497. Epub 2015 Oct 20.

Cat. No.	Product name	Field of application
DC58046	C12-200	C12-200 is a well-known cationic lipid used in the formulation of lipid nanoparticles (LNPs) for the delivery of therapeutic nucleic acids, including siRNA, mRNA, and CRISPR components. It is widely recognized for its high in vivo potency at low doses and is often used as a positive control ionizable lipid in research exploring new ionizable lipids.